vimarsana.com
Home
Live Updates
The FLOW-AF multicenter, randomized controlled trial shows A
The FLOW-AF multicenter, randomized controlled trial shows A
The FLOW-AF multicenter, randomized controlled trial shows Ablacon's Electrographic Flow® (EGF®) Mapping software (Ablamap®) results in improved ablation outcomes in persistent atrial fibrillation
/PRNewswire/ -- Ablacon, Inc., an Ajax Health and Zeus Health-backed developer of an innovative mapping system to guide the treatment of atrial fibrillation...
Related Keywords
Boston ,
Massachusetts ,
United States ,
Duke Rohlen ,
David Haines ,
Ablacon Ablamap ,
Vivek Reddy ,
Ablacon Inc ,
Prnewswire Ablacon Inc ,
Ajax Health ,
Zeus Health Backed ,
Late Breaking Clinical Trials ,
Scientific Advisory Board ,
Menlo Park ,
Healthquest Capital ,
Polaris Partners ,
Ablacon ,
Nc ,